How Martha was paid
$21.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Pension | Other | Total |
|---|---|---|---|---|---|---|---|
| Geoffrey S. MarthaChairman and Chief Executive Officer | $1,350,000 | $12,625,000 | $4,800,365 | $1,883,250 | — | $581,443 | $21,240,058 |
| Thierry PiétonExecutive Vice President and Chief Financial Officer | $138,517 | $4,190,625 | $600,056 | $141,975 | — | $141,274 | $5,212,448 |
| Sean M. SalmonFormer EVP & President, Cardiovascular Portfolio | $884,654 | $4,537,157 | $1,725,131 | $823,050 | $382,886 | $43,719 | $8,396,597 |
| Brett A. WallEVP & President, Neuroscience Portfolio | $774,519 | $4,537,157 | $1,725,131 | $720,750 | — | $363,656 | $8,121,213 |
| Gregory L. SmithEVP Enterprise Operations | $894,560 | $4,537,157 | $1,725,131 | $832,350 | — | $94,784 | $8,083,981 |
| Gary L. CoronaFormer SVP Corporate Finance (former Interim CFO) | $466,346 | $3,089,088 | $25,002 | — | — | $214,812 | $3,795,248 |
| Karen L. ParkhillFormer Executive Vice President and Chief Financial Officer | $262,856 | — | — | — | — | $7,823 | $270,679 |
What changed and why
- $21.2M$21,240,058 CEO total compensation increased from $20,084,630 in fiscal 2024.
- $12.6M$12,625,000 CEO stock awards represented the largest component of fiscal 2025 compensation.
- $4.8M$4,800,365 CEO option awards were granted with a $80.00 exercise price.
- $2M$2,025,000 was the CEO’s target Medtronic Incentive Plan opportunity.
- $141K$141,274 of Thierry Piéton’s other compensation represented relocation expenses, including forfeited prior-employer compensation in stock awards.
- 92.93%92.93% of votes cast supported executive compensation at the 2024 annual general meeting.
Other Medtronic proxy statements
- 2026 proxy statement
Geoff Martha paid $22.9M (+8% on the year), pay ratio 303:1.
Filed Aug 17, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.